Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis.

Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, Abraldes JG, Bosques-Padilla F, Verna EC, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross D, Lucey MR, Louvet A, Mathurin P, Garcia-Tsao G, Ho SB, Tu XM, Bataller R, Stärkel P, Fouts DE, Schnabl B.

Hepatology. 2019 Jun 22. doi: 10.1002/hep.30832. [Epub ahead of print]

PMID:
31228214
2.

Acute kidney injury is associated with higher mortality and healthcare costs in hospitalized patients with cirrhosis.

Karagozian R, Bhardwaj G, Wakefield DB, Verna EC.

Ann Hepatol. 2019 May 23. pii: S1665-2681(19)30347-3. doi: 10.1016/j.aohep.2019.03.011. [Epub ahead of print]

3.

Identifying Risk of Alcohol Relapse after Liver Transplantation: What tools do we need?

Shen NT, Shenoy A, Brown RS Jr, Verna EC.

Liver Transpl. 2019 Jun 5. doi: 10.1002/lt.25579. [Epub ahead of print]

PMID:
31166651
4.

Preliminary Screening Results Outside the 1945-1965 Birth Cohort: A Forgotten Population for Hepatitis C?

Winetsky D, Zucker J, Slowikowski J, Scherer M, Verna EC, Gordon P.

Open Forum Infect Dis. 2019 Apr 10;6(5):ofz178. doi: 10.1093/ofid/ofz178. eCollection 2019 May.

5.

Escherichia coli Harboring mcr-1 in a Cluster of Liver Transplant Recipients: Detection through Active Surveillance and Whole-Genome Sequencing.

Macesic N, Khan S, Giddins MJ, Freedberg DE, Whittier S, Green DA, Furuya EY, Verna EC, Annavajhala MK, Gomez-Simmonds A, Uhlemann AC.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02680-18. doi: 10.1128/AAC.02680-18. Print 2019 Jun.

PMID:
30962343
6.

Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study.

Jacobson IM, Poordad F, Firpi-Morell R, Everson GT, Verna EC, Bhanja S, Hwang P, Caro L, Robertson M, Charles ED, Platt H.

Clin Transl Gastroenterol. 2019 Apr;10(4):e00007. doi: 10.14309/ctg.0000000000000007.

7.

Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.

DiNorcia J, Florman SS, Haydel B, Tabrizian P, Ruiz RM, Klintmalm GB, Senguttuvan S, Lee DD, Taner CB, Verna EC, Halazun KJ, Hoteit M, Levine MH, Chapman WC, Vachharajani N, Aucejo F, Nguyen MH, Melcher ML, Tevar AD, Humar A, Mobley C, Ghobrial M, Nydam TL, Amundsen B, Markmann JF, Berumen J, Hemming AW, Langnas AN, Carney CA, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Markovic D, Busuttil RW, Agopian VG.

Ann Surg. 2019 Mar 5. doi: 10.1097/SLA.0000000000003253. [Epub ahead of print]

PMID:
30870180
8.

Association Between Renal Function Pattern and Mortality in Patients with Cirrhosis.

Cullaro G, Verna EC, Lai JC.

Clin Gastroenterol Hepatol. 2019 Feb 1. pii: S1542-3565(19)30090-4. doi: 10.1016/j.cgh.2019.01.043. [Epub ahead of print]

PMID:
30716479
9.

Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study.

Lai JC, Rahimi RS, Verna EC, Kappus MR, Dunn MA, McAdams-DeMarco M, Haugen CE, Volk ML, Duarte-Rojo A, Ganger DR, O'Leary JG, Dodge JL, Ladner D, Segev DL.

Gastroenterology. 2019 May;156(6):1675-1682. doi: 10.1053/j.gastro.2019.01.028. Epub 2019 Jan 19.

PMID:
30668935
10.

Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes.

Kriss M, Verna EC, Rosen HR, Lozupone CA.

Transplantation. 2019 Apr;103(4):668-678. doi: 10.1097/TP.0000000000002568.

PMID:
30507741
11.

Deceased Brain Dead Donor Liver Transplantation and Utilization in the United States: Nighttime and Weekend Effects.

Carpenter DJ, Chiles MC, Verna EC, Halazun KJ, Emond JC, Ratner LE, Mohan S.

Transplantation. 2019 Jul;103(7):1392-1404. doi: 10.1097/TP.0000000000002533.

PMID:
30444802
12.

Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction.

Lange NW, Salerno DM, Sammons CM, Jesudian AB, Verna EC, Brown RS Jr.

Clin Transplant. 2018 Dec;32(12):e13415. doi: 10.1111/ctr.13415. Epub 2018 Oct 27.

PMID:
30276862
13.

Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy.

Chan C, Schiano T, Agudelo E, Paul Haydek J, Hoteit M, Laurito MP, Norvell JP, Terrault N, Verna EC, Yang A, Levitsky J.

Am J Transplant. 2018 Oct;18(10):2506-2512. doi: 10.1111/ajt.15053. Epub 2018 Aug 30.

PMID:
30075485
14.

Genomic Surveillance Reveals Diversity of Multidrug-Resistant Organism Colonization and Infection: A Prospective Cohort Study in Liver Transplant Recipients.

Macesic N, Gomez-Simmonds A, Sullivan SB, Giddins MJ, Ferguson SA, Korakavi G, Leeds D, Park S, Shim K, Sowash MG, Hofbauer M, Finkel R, Hu Y, West J, Toussaint NC, Greendyke WG, Miko BA, Pereira MR, Whittier S, Verna EC, Uhlemann AC.

Clin Infect Dis. 2018 Aug 31;67(6):905-912. doi: 10.1093/cid/ciy199.

PMID:
29718144
15.

Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.

Brandl K, Hartmann P, Jih LJ, Pizzo DP, Argemi J, Ventura-Cots M, Coulter S, Liddle C, Ling L, Rossi SJ, DePaoli AM, Loomba R, Mehal WZ, Fouts DE, Lucey MR, Bosques-Padilla F, Mathurin P, Louvet A, Garcia-Tsao G, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross D, Stärkel P, Ho SB, Bataller R, Schnabl B.

J Hepatol. 2018 Aug;69(2):396-405. doi: 10.1016/j.jhep.2018.03.031. Epub 2018 Apr 12.

PMID:
29654817
16.

Updated Hepatitis B Guidance: Implications for liver transplant patients.

Verna EC.

Liver Transpl. 2018 Apr;24(4):465-469. doi: 10.1002/lt.25037. No abstract available.

17.

Durable Clinical and Immunologic Advantage of Living Donor Liver Transplantation in Children.

Przybyszewski EM, Verna EC, Lobritto SJ, Martinez M, Vittorio JM, Fox AN, Samstein B, Kato T, Griesemer AD, Emond JC.

Transplantation. 2018 Jun;102(6):953-960. doi: 10.1097/TP.0000000000002110.

PMID:
29369249
18.

Early Postoperative Neutrophil Gelatinase-Associated Lipocalin Predicts the Development of Chronic Kidney Disease After Liver Transplantation.

Cullaro G, Pisa JF, Brown RS Jr, Wagener G, Verna EC.

Transplantation. 2018 May;102(5):809-815. doi: 10.1097/TP.0000000000002075.

19.

Hepatitis C viremic donors for hepatitis C nonviremic liver transplant recipients: Ready for prime time?

Verna EC, Goldberg DS.

Liver Transpl. 2018 Jan;24(1):12-14. doi: 10.1002/lt.24985. No abstract available.

20.

Ascites Neutrophil Gelatinase-Associated Lipocalin Identifies Spontaneous Bacterial Peritonitis and Predicts Mortality in Hospitalized Patients with Cirrhosis.

Cullaro G, Kim G, Pereira MR, Brown RS Jr, Verna EC.

Dig Dis Sci. 2017 Dec;62(12):3487-3494. doi: 10.1007/s10620-017-4804-7. Epub 2017 Nov 2.

PMID:
29098551
21.

HCV treatment in patients with decompensated liver disease.

Verna EC.

Clin Liver Dis (Hoboken). 2017 Oct 31;10(4):83-86. doi: 10.1002/cld.663. eCollection 2017 Oct. Review. No abstract available.

22.

No country for old livers? Examining and optimizing the utilization of elderly liver grafts.

Halazun KJ, Rana AA, Fortune B, Quillin RC 3rd, Verna EC, Samstein B, Guarrera JV, Kato T, Griesemer AD, Fox A, Brown RS Jr, Emond JC.

Am J Transplant. 2018 Mar;18(3):669-678. doi: 10.1111/ajt.14518. Epub 2017 Nov 8.

23.

Vaccination to prevent de novo hepatitis B: Are there patients who do not need antiviral prophylaxis?

Verna EC.

Liver Transpl. 2017 Oct;23(10):1253-1254. doi: 10.1002/lt.24858. No abstract available.

24.

Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.

Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florman SS, Haydel B, Hoteit M, Levine MH, Lee DD, Taner CB, Verna EC, Halazun KJ, Abdelmessih R, Tevar AD, Humar A, Aucejo F, Chapman WC, Vachharajani N, Nguyen MH, Melcher ML, Nydam TL, Mobley C, Ghobrial RM, Amundsen B, Markmann JF, Langnas AN, Carney CA, Berumen J, Hemming AW, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Busuttil RW.

Ann Surg. 2017 Sep;266(3):525-535. doi: 10.1097/SLA.0000000000002381.

PMID:
28654545
25.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators.

N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.

26.

Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.

Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS Jr, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR.

Hepatology. 2017 Oct;66(4):1090-1101. doi: 10.1002/hep.29258. Epub 2017 Sep 4.

27.

Transplanting patients with active bacterial infection.

Verna EC, Pereira MR.

Clin Liver Dis (Hoboken). 2017 Apr 20;9(4):81-85. doi: 10.1002/cld.624. eCollection 2017 Apr. Review. No abstract available.

28.

Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.

Verna EC.

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):211-223. doi: 10.1016/S2468-1253(16)30120-0. Epub 2017 Feb 9. Review.

PMID:
28404136
29.

Management of Advanced Fibrosis in the Context of Hepatitis C Virus Infection.

Verna EC.

Top Antivir Med. 2017 Feb/Mar;25(1):7-11. Review.

30.

HCV Antiviral Therapy in Liver Transplant Candidates and Recipients With Renal Insufficiency.

Verna EC, Brown RS Jr.

Transplantation. 2017 May;101(5):924-932. doi: 10.1097/TP.0000000000001688. Review.

PMID:
28212220
31.

The dynamic landscape of liver transplant in the era of effective hepatitis C virus therapy.

Verna EC.

Hepatology. 2017 Mar;65(3):763-766. doi: 10.1002/hep.29054. Epub 2017 Feb 6. No abstract available.

PMID:
28093781
32.

Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients.

Sharaiha RZ, Kumta NA, Saumoy M, Desai AP, Sarkisian AM, Benevenuto A, Tyberg A, Kumar R, Igel L, Verna EC, Schwartz R, Frissora C, Shukla A, Aronne LJ, Kahaleh M.

Clin Gastroenterol Hepatol. 2017 Apr;15(4):504-510. doi: 10.1016/j.cgh.2016.12.012. Epub 2016 Dec 23.

PMID:
28017845
33.

Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.

Levitsky J, Verna EC, O'Leary JG, Bzowej NH, Moonka DK, Hyland RH, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault NA.

N Engl J Med. 2016 Nov 24;375(21):2106-2108. No abstract available.

PMID:
27959735
34.

Managing nonalcoholic fatty liver disease in patients living with HIV.

Tafesh ZH, Verna EC.

Curr Opin Infect Dis. 2017 Feb;30(1):12-20. doi: 10.1097/QCO.0000000000000344. Review.

PMID:
27941355
35.

We can cure hepatitis C virus after transplant, but what is the best regimen?

Verna EC.

Liver Transpl. 2016 Nov;22(11):1463-1465. doi: 10.1002/lt.24639. No abstract available.

36.

Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.

Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, Kato T, Verna EC, Emond JC, Brown RS Jr.

Ann Surg. 2017 Mar;265(3):557-564. doi: 10.1097/SLA.0000000000001966.

PMID:
27611615
37.

Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease.

Uhde M, Ajamian M, Caio G, De Giorgio R, Indart A, Green PH, Verna EC, Volta U, Alaedini A.

Gut. 2016 Dec;65(12):1930-1937. doi: 10.1136/gutjnl-2016-311964. Epub 2016 Jul 25.

38.

Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.

Gordon FD, Goldberg DS, Goodrich NP, Lok AS, Verna EC, Selzner N, Stravitz RT, Merion RM.

Liver Transpl. 2016 Sep;22(9):1214-22. doi: 10.1002/lt.24496. Epub 2016 Aug 2.

39.

Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance.

Berk PD, Verna EC.

Clin Liver Dis. 2016 May;20(2):245-62. doi: 10.1016/j.cld.2015.10.007. Epub 2016 Feb 18. Review.

40.

Progression of Incidental Intraductal Papillary Mucinous Neoplasms of the Pancreas in Liver Transplant Recipients.

Dorfman V, Verna EC, Poneros JM, Sethi A, Allendorf JD, Gress FG, Schrope BA, Chabot JA, Gonda TA.

Pancreas. 2016 Apr;45(4):620-5. doi: 10.1097/MPA.0000000000000510.

PMID:
26495782
41.

Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation.

Bhatt BD, Lukose T, Siegel AB, Brown RS Jr, Verna EC.

J Gastrointest Oncol. 2015 Oct;6(5):459-68. doi: 10.3978/j.issn.2078-6891.2015.050.

42.
43.

The Role of Sarcopenia and Frailty in Hepatic Encephalopathy Management.

Lucero C, Verna EC.

Clin Liver Dis. 2015 Aug;19(3):507-28. doi: 10.1016/j.cld.2015.04.003. Review.

PMID:
26195205
44.

Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients.

Pereira MR, Scully BF, Pouch SM, Uhlemann AC, Goudie S, Emond JE, Verna EC.

Liver Transpl. 2015 Dec;21(12):1511-9. doi: 10.1002/lt.24207.

45.

Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease.

Verna EC, Patel J, Bettencourt R, Nguyen P, Hernandez C, Valasek MA, Kisselva T, Brenner DA, Loomba R.

Aliment Pharmacol Ther. 2015 Sep;42(5):582-90. doi: 10.1111/apt.13292. Epub 2015 Jun 29.

46.

Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma.

Siegel AB, El-Khoueiry AB, Finn RS, Guthrie KA, Goyal A, Venook AP, Blanke CD, Verna EC, Dove L, Emond J, Kato T, Samstein B, Busuttil R, Remotti H, Coffey A, Brown RS Jr.

Liver Cancer. 2015 Mar;4(2):115-25. doi: 10.1159/000367734.

47.

Hepatitis C treatment in patients on the liver transplant waiting list.

Verna EC, O'Leary JG.

Curr Opin Organ Transplant. 2015 Jun;20(3):242-50. doi: 10.1097/MOT.0000000000000200. Review.

PMID:
25944239
48.
49.

Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.

Verna EC, Saxena V, Burton JR Jr, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, Terrault NA; CRUSH-C Consortium.

Transplantation. 2015 Aug;99(8):1644-51. doi: 10.1097/TP.0000000000000629.

50.

Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients.

Hsu CC, Goyal A, Iuga A, Krishnamoorthy S, Lee V, Verna EC, Wang S, Chen FN, Rodriguez R, Emond J, Berk P, Lefkowitch J, Dove L, Brown RS Jr, Siegel AB.

Clin Transl Gastroenterol. 2015 Feb 5;6:e74. doi: 10.1038/ctg.2014.22.

Supplemental Content

Loading ...
Support Center